Glucocorticoids in rheumatoid arthritis still on first line: the reasons

References

• Hench PS, Kendall EC, Slocumb CH, et al. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic). 1950;85:545–666.
   PubMedGoogle Scholar
• Palmowski Y, Buttgereit T, Buttgereit F. The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend. Rheumatology (Oxford). 2019;58:580–587.
   PubMed Web of Science ®Google Scholar
• Straub RH, Cutolo M. Glucocorticoids and chronic inflammation. Rheumatology (Oxford). 2016;55:ii6–ii14.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Weidler C, Naumann H, et al. Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? Arthritis Rheum. 2005;52(6):1711–1720.
   PubMedGoogle Scholar
• Fenton C, Martin C, Jones R, et al. Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids. Ann Rheum Dis. 2021;80:250–260.
   PubMed Web of Science ®Google Scholar
• Hayes K, Panaccio MP, Goel N, et al. Patient characteristics and indicators of treatment initiation with repository corticotropin injection in patients with rheumatoid arthritis: a claims database analysis. Rheumatol Ther. 2021 Jan 5. Epub ahead of print. DOI:10.1007/s40744-020-00272-x.
   PubMed Web of Science ®Google Scholar
• Savage O, Davis PS, Chapman L, et al. Corticotrophin (ACTH) in rheumatoid arthritis. Ann Rheum Dis. 1959;18:100–110.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Seriolo B, Craviotto C, et al. Circadian rhythms in RA. Ann Rheum Dis. 2003;62:593–596.
   PubMed Web of Science ®Google Scholar
• Cutolo M. Circadian rhythms and rheumatoid arthritis. Joint Bone Spine. 2019 May;86:327–333.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371:205–214.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013;72:204–210.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Hopp M, Liebscher S, et al. Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. RMD Open. 2017;3:e000426.
   PubMed Web of Science ®Google Scholar
• Miler E, Stapleton PP, Mapplebeck S, et al. Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis. Int J Rheum Dis. 2019;22:1900–1904.
   PubMed Web of Science ®Google Scholar
• Lorenz LJ, Hall JC, Rosbash M. Expression of a drosophila mRNA is under circadian clock control during pupation. Development. 1989;107:869–880.
   PubMed Web of Science ®Google Scholar
• Berardicurti O, Ruscitti P, Pavlych V, et al. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. Expert Rev Clin Pharmacol. 2020;13:593–604.
   PubMed Web of Science ®Google Scholar
• Koenen M, Culemann S, Vettorazzi S, et al. Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis. Ann Rheum Dis. 2018;77:1610–1618.
   PubMed Web of Science ®Google Scholar
• Tardito S, Martinelli G, Soldano S, et al. Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review. Autoimmun Rev. 2019;18:102397.
   PubMed Web of Science ®Google Scholar
• Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:3371–3380.
   PubMed Web of Science ®Google Scholar
• Louveau B, De Rycke Y, Lafourcade A, et al. Effect of cumulative exposure to corticosteroid and DMARD on radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort. Rheumatology (Oxford). 2018;57:1563–1573.
   PubMed Web of Science ®Google Scholar
• Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl 4):iv9–13.
   PubMedGoogle Scholar
• Strehl C, Bijlsma JW, De Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75:952–957.
   PubMed Web of Science ®Google Scholar
• Santiago T, Voshaar M, De Wit M, et al. Patients’ and rheumatologists’ perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study. Rheumatology (Oxford). 2021;keaa785. Epub ahead of print. doi:10.1093/rheumatology/keaa785
   PubMedGoogle Scholar
• Hartman L, Rasch LA, Klausch T, et al. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. Trials. 2018;19:67.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Buttgereit F, Bernasconi C, et al. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet. 2020;396:267–276.
   PubMed Web of Science ®Google Scholar
• Paolino S, Pacini G, Patanè M, et al. Interactions between microbiota, diet/nutrients and immune/inflammatory response in rheumatic diseases: focus on rheumatoid arthritis. Reumatologia. 2019;57:151–157.
   PubMedGoogle Scholar